Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1960 1
1962 1
1963 4
1964 1
1965 2
1967 1
1968 1
1971 1
1972 5
1973 1
1977 2
1979 4
1980 4
1981 13
1982 18
1983 13
1984 24
1985 32
1986 28
1987 26
1988 47
1989 40
1990 44
1991 54
1992 58
1993 74
1994 97
1995 117
1996 115
1997 157
1998 168
1999 175
2000 194
2001 199
2002 279
2003 354
2004 431
2005 601
2006 681
2007 813
2008 971
2009 1203
2010 1282
2011 1447
2012 1928
2013 2201
2014 2606
2015 2998
2016 3211
2017 3600
2018 4019
2019 4867
2020 5858
2021 6502
2022 7903
2023 7906
2024 6876
2025 13

Text availability

Article attribute

Article type

Publication date

Search Results

62,914 results

Results by year

Filters applied: . Clear all
Page 1
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.
Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Wu MJ, et al. Among authors: sun y. Science. 2024 Jul 12;385(6705):eadl6173. doi: 10.1126/science.adl6173. Epub 2024 Jul 12. Science. 2024. PMID: 38991060
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data.
Chen Z, Chen Y, Sun Y, Tang L, Zhang L, Hu Y, He M, Li Z, Cheng S, Yuan J, Wang Z, Wang Y, Zhao J, Gong J, Zhao L, Cao B, Li G, Zhang X, Dong B, Shen L. Chen Z, et al. Among authors: sun y. Signal Transduct Target Ther. 2024 Aug 26;9(1):222. doi: 10.1038/s41392-024-01932-y. Signal Transduct Target Ther. 2024. PMID: 39183247 Free PMC article.
Single-Cell Transcriptomics Applied in Plants.
Sun Y, Sun J, Lin C, Zhang J, Yan H, Guan Z, Zhang C. Sun Y, et al. Cells. 2024 Sep 17;13(18):1561. doi: 10.3390/cells13181561. Cells. 2024. PMID: 39329745 Free PMC article. Review.
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).
Xia F, Wang Y, Wang H, Shen L, Xiang Z, Zhao Y, Zhang H, Wan J, Zhang H, Wang Y, Wu R, Wang J, Yang W, Zhou M, Zhou S, Chen Y, Zhang Z, Wu X, Xuan Y, Wang R, Sun Y, Tong T, Zhang X, Wang L, Huang D, Sheng W, Yan H, Yang X, Shen Y, Xu Y, Zhao R, Mo M, Cai G, Cai S, Xu Y, Zhang Z. Xia F, et al. Among authors: sun y. J Clin Oncol. 2024 Oct;42(28):3308-3318. doi: 10.1200/JCO.23.02261. Epub 2024 Jul 1. J Clin Oncol. 2024. PMID: 38950321 Clinical Trial.
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC.
Li YS, Lai WP, Yin K, Zheng MM, Tu HY, Guo WB, Li L, Lin SH, Wang Z, Zeng L, Jiang BY, Chen ZH, Zhou Q, Zhang XC, Yang JJ, Zhong WZ, Yang XN, Wang BC, Pan Y, Chen HJ, Xiao FM, Sun H, Sun YL, Bai XY, Ke EE, Lin JX, Liu SM, Li Y, Luo OJ, Wu YL. Li YS, et al. Among authors: sun yl. Cell Rep. 2024 Aug 27;43(8):114613. doi: 10.1016/j.celrep.2024.114613. Epub 2024 Aug 7. Cell Rep. 2024. PMID: 39116206 Free article.
62,914 results
You have reached the last available page of results. Please see the User Guide for more information.